A Phase 1, Open-Label, Multicenter Study of KYV-101-001, an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects with Refractory Lupus Nephritis
![](https://researchstudies.cuanschutz.edu/Content/images/study-category-images/bones-muscles-and-joints.jpg)
Description
Apheresis (collection of white blood cells) followed by lymphodepletion (medications to weaken, temporarily, your immune system so that the CAR T cells can grow and work in the body, followed by single infusion of KYV-101 (the CAR T cells made specifically for your body)
Details
Adult
* age of 18 or older * lupus nephritis that has not responded to other therapies * clinical diagnosis of SLE * active, biopsy-proven, proliferative lupus nephritis class III or IV * inadequate response (urine protein equal to or greater than 1... 5 g/24 hrs after at least 6 months of treatment with 2 or more conventional therapies * up to date on vaccinations, including against COVID-19 * not pregnant
MoreLocations
Outpatient CTRC
Renal Research Center
University of Colorado Hospital
Principal Investigator
![Photograph of Amber Podoll](https://som.ucdenver.edu/FIMS/Content/faculty/28666/CU-Doctors-28666.jpg)
Amber Podoll
Study ID
Protocol Number: 22-1850
More information available at ClinicalTrials.gov: NCT05938725
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers